Pages

▼

Take a look here

▼

Sunday, November 22, 2026

In the NEWS: FSGS and Finerenone

 For decades, FSGS management meant RAS blockade, off-label immunosuppression, and hope. 2026 changed that: sparsentan became the first FDA-approved drug for FSGS in April, and now a new JASN analysis suggests finerenone may slow eGFR loss in FSGS too.


•       Design: Prespecified analysis of FIND-CKD — the phase 3, double-blind RCT of finerenone vs placebo in 1,584 adults with non-diabetic CKD, on top of maximally tolerated RAS blockade, followed 32 months.  FSGS cohort: 215 patients (of 903 with glomerular disease) — 108 primary, 107 secondary; 167 biopsy-proven. Mean baseline eGFR ~45 mL/min/1.73 m².

Results:

Outcome

Finerenone vs placebo

Total eGFR slope (32 mo)

+1.3 mL/min/1.73 m²/yr slower decline (95% CI 0.5–2.2; P = .002)

eGFR slope, biopsy-proven FSGS (n = 167)

+1.4 mL/min/1.73 m²/yr

Placebo eGFR decline

~4–5 mL/min/1.73 m²/yr

UPCR at 12 months

−41% (95% CI 26–53%)

UPCR < 700 mg/g at 12 months

OR 6.8 (95% CI 3.0–17.2)

Kidney composite (≥57% eGFR decline or kidney failure)

HR 0.58 (95% CI 0.30–1.15) — not significant

Hyperkalemia-related AEs

15% vs 20%

Notable: the eGFR-slope benefit in FSGS (1.3) is nearly double that of the overall FIND-CKD population (0.7 mL/min/1.73 m²/yr). 

This is good as it is a  randomized, placebo-controlled, prespecified, a surprisingly large FSGS cohort, and a hard-ish endpoint (eGFR slope) — something DUPLEX did not achieve for sparsentan at 108 weeks despite superior proteinuria reduction vs irbesartan.

Some caveats:  
Subgroup analysis; the composite outcome was underpowered and not significant.
Half the cohort had secondary FSGS — mechanism and response may differ from primary (podocytopathic) FSGS. 
 Only ~17% of the overall trial was on an SGLT2 inhibitor at baseline; the additive effect on top of SGLT2i in FSGS is unknown. 
Not head-to-head with sparsentan; the comparator was placebo, not an active RASi.

Finerenone is not FDA-approved for FSGS or non-diabetic CKD. But I am thinking it will be approved for non diabetic proteinuric kidney disease soon. 

•       Open question: sequencing — SGLT2i first? Finerenone? ERA plus finerenone? Heerspink has called for a dedicated (e.g., SMART-design) trial.


FSGS therapies: approval status (as of November 2026)

Drug

Class

US status for FSGS

Key evidence

Practical notes

Sparsentan (Filspari)

Dual endothelin-A / AT1 receptor antagonist (DEARA)

FDA full approval, Apr 13, 2026 — to reduce proteinuria in patients ≥8 yrs with FSGS without nephrotic syndrome. First and only FSGS-approved drug.

DUPLEX (phase 3), DUET (phase 2)

Replaces (not added to) ACEi/ARB. REMS for hepatotoxicity/embryo-fetal toxicity. Also approved for IgAN.

Finerenone (Kerendia)

Non-steroidal MRA

Not approved for FSGS. sNDA for non-diabetic CKD under FDA review. Approved for CKD + T2D, CKD + T1D (Sep 2026), HFmrEF/HFpEF.

FIND-CKD FSGS analysis (JASN 2026)

Add-on to RASi; monitor K⁺.

Dapagliflozin / empagliflozin

SGLT2 inhibitor

Approved for CKD broadly (not FSGS-specific)

DAPA-CKD / EMPA-KIDNEY subgroups

Effect in FSGS modest/uncertain; reasonable background therapy.

Apecotrep

TRPC6 inhibitor

Investigational — phase 3 recruiting

Phase 2 (12 wk): −40% proteinuria vs placebo at 20 mg

Likely an add-on rather than standalone.

APOL1 inhibitors

APOL1 channel inhibition

Investigational

Ongoing trials in APOL1-mediated kidney disease

Genotype-targeted (APOL1 high-risk).



The future of FSGS looks like CKD care has become: layered, mechanism-matched therapy — RAS/ET blockade, SGLT2i, MRA — with targeted agents (TRPC6, APOL1, B-cell) for the right phenotype.






No comments:

Post a Comment